Research Phases | Pre-Clinical Biomarkers | Clinical Proteomics

Research Phases

    Regardless of the stage of your research, Biognosys’ next-generation proteomics solutions help you accelerate and de-risk your drug research and development with unprecedented precision, depth, and scale.

    Biognosys’ proteomics solutions provide a versatile platform to provide integrated insights on protein expression, function and structure across the drug discovery and development pipeline. From novel target discovery and validation, to pre-clinical mechanism of action studies or biomarker discovery in clinical studies, our next-generation proteomics applications will give you the key insights you need to advance your research.

    Our proteomics solutions provide the versatility and quick delivery of results needed to inform go/no-go decision-making throughout the drug discovery process. Using Biognosys’s Discovery Proteomics workflows to generate functional data offers the opportunity to discover new pathways and targets, and to develop first-in-class therapeutics.

    Biognosys’ drug Target Deconvolution approach Limited Proteomics Mass Spectrometry (LiP-MS) can effectively identify protein drug targets and characterize their binding properties in complex proteomes without the need for compound modification or labeling.

    In this specific example, LiP-MS was used to distinguish the specificity and selectivity of different kinase and phosphatase inhibitors.

    Our mass spectrometry-based proteomics tools and techniques provide a flexible platform that works across all types of biological samples, species, and disease indications. This enables proteomics markers identified in cellbased and animal studies to be validated in the pre-clinical setting to increase confidence in your therapeutic approach, identify potential off-target interactions, side effects and improve chances of success in clinical trials.

    Mechanism of Action

    Profiling of the proteomic response to therapy in animal models

    Proteomic profiling of tissue or tumor samples from animal models of disease reveals detailed information about the proteins and pathways involved in response to therapy.

    For example, Biognosys’ Discovery Proteomics was used to investigate the role of immune cell depletion in the response to PD-1 blockade in syngeneic mouse models.

    Our mass spectrometry workflows offer high-precision, quantitative proteomic data at unprecedented depth and reproducibility over thousands of samples taken at multiple timepoints. We are bringing Good Clinical Practice (GCP)-compliant workflows at our service facility in Switzerland, making proteomics the method of choice for large-scale translational and clinical studies.

    These case studies show the benefit of proteomics to identify and measure novel biomarkers in samples ranging from biological fluids such as blood plasma/serum or urine to fresh frozen tissue and FFPE sections.


    Access our knowledge base with relevant resources and guiding information.


      Close banner

      New: Drug Target Validation

      Reveal Binding Sites with Structural Proteomics

      New: Drug Target Validation

      Reveal Compound Binding Sites with Structural Proteomics

      Learn More